GLP-1 receptor agonists, a class of drugs including Ozempic and Wegovy, have been linked to smell and taste impairment in patients with diabetes, according to a new study. The findings raise concerns about potential side effects beyond the well-known gastrointestinal issues.
Study details and findings
The research, published in a peer-reviewed journal, analyzed data from thousands of diabetes patients using GLP-1 drugs. It found that approximately 1 in 10 patients reported changes in their sense of smell or taste, with some experiencing complete loss. The mechanism is believed to involve the drugs' action on GLP-1 receptors in the olfactory and gustatory systems.
Lead researcher Dr. Sarah Chen stated, "Our study highlights a previously underrecognized side effect that can significantly impact quality of life. Patients should be aware and report any changes to their healthcare provider."
Broader implications
GLP-1 drugs are widely prescribed for type 2 diabetes and obesity. The study adds to a growing list of potential side effects, including nausea, vomiting, and rare cases of pancreatitis. The U.S. Food and Drug Administration is reviewing the data to determine if label updates are needed.
Patient advocacy groups are calling for more research. "This is a serious issue that affects daily life, from enjoying food to detecting danger like smoke," said Jane Miller of the Diabetes Patient Alliance.
